卒論・修論

学生さんの卒論・修論 発表実績

(前任大学での研究指導を含む)

2024年度

修論

• Estimation of health-related quality of life and cost-effectiveness analysis of sacituzumab govitecan in metastatic triple-negative breast cancer.

卒論

• Cost-effectiveness analysis of NALIRIFOX as first-line therapy for metastatic pancreatic ductal adenocarcinoma in Japan

• Cost-effectiveness analysis of cemiprimab as second-line therapy for patients with metastatic or recurrent cervical cancer in Japan

• Cost-effectiveness analysis of fruquintinib as third-line therapy for patients with unresectable advanced or recurrent colorectal cancer

• Cost-effectiveness analysis of tripalimumab for metastatic or recurrent triple negative breast cancer in Japan

• Cost-effectiveness analysis of dostarlimab plus chemotherapy as first-line treatment for metastatic non-squamous non-small cell lung cancer

• Cost-effectiveness analysis of dabrafenib + trametinib combination therapy for non-small cell lung cancer with BRAF V600E mutation

• Cost-effectiveness analysis of sugemarimab plus chemotherapy as primary treatment for advanced esophageal squamous cell carcinoma

• Cost-effectiveness analysis of mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer in Japan

2023年度

卒論

• Cost-effectiveness analysis of pembrolizumab for persistent, recurrent, or metastatic cervical cancer in Japan

• Implementation and educational use of partitioned survival analysis using R

• Cost-effectiveness analysis of blinatumomab for advanced acute lymphoblastic leukemia in Japan

• Cost-effectiveness analysis of tremelimumab as first-line therapy for metastatic non-small cell lung cancer in Japan

• Economic evaluation of duvelisib versus ofatumumab in relapsed/refractory CLL/SLL in Japan

• Cost-effectiveness analysis of pembrolizumab for advanced colorectal cancer with MSI-High or dMMR in Japan

• Clinical evidence for cell and gene therapies approved in Japan and challenges in economic evaluation

2022年度

卒論

• Cost-Effectiveness Analysis of Cemiplimab As Second-Line Therapy for Recurrent Cervical Cancer in Japan 

• Cost-Effectiveness Analysis of Erlotinib Plus Bevacizumab As First-Line Therapy for Advanced EGFR Mutation-Positive Non-Squamous Non-Small Cell Lung Cancer in Japan

• Cost-Effectiveness Analysis of Sacituzumab Govitecan As Second-Line Treatment for Metastatic Triple-Negative Breast Cancer in Japan　

• Cost-Effectiveness of Nivolumab Plus Ipilimumab in Gastro-Oesophageal Cancer in Japan

• Economic Evaluation of Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in Japan

• Economic Evaluation of Nanoparticle Albumin-Bound paclitaxel for Previously Treated Advanced NSCLC in Japan　

着任以前の指導

2022/05　Cost-Effectiveness Analysis of Nivolumab Plus Chemotherapy Vs Chemotherapy in Patients with Advanced Gastric Cancer in Japan 

2021/11　Cost-Effectiveness of Preventive Intervention for Prediabetes in Japan

2021/11　Economic Evaluation of Nivolumab Plus Ipilimumab in Advanced Renal-Cell Carcinoma in Japan  

2021/04　Cost-effectiveness of nab-paclitaxel and gemcitabine vs gemcitabine monotherapy for unresectable metastatic pancreatic cancer patients in Japan

2020/10　切除不能膵癌に対するゲムシタビン+ナブパクリタキセル併用療法の費用対効果分析

2019/11　進行性の腎細胞がんに対する1次治療としてのニボルマブ+イピリムマブ併用療法の費用対効果評価の試み

2019/11　切除不能の局所進行非小細胞性肺癌に対する維持治療としてのデュルバルマブの費用効果分析

2019/11　切除不能肝細胞癌に対する１次治療としてのレンバチニブの費用効果分析 

2019/03　Ⅳ期扁平上皮非小細胞肺癌に対する１次治療としてのネシツムマブの費用対効果評価の試み 

2019/03　転移・再発性の悪性軟部肉腫に対する2次治療としてのトラベクテジンの費用対効果評価の試み 

2019/03　日本における転移性膵臓癌に対するFOLFIRINOX療法の費用対効果の検討  

2018/09　Development of an economic model to assess the cost-effectiveness of proton beam therapy in patients with hepatocellular carcinoma In Japan  

2018/09　Estimation of cost parameters using claims database for use in cost-effectiveness analysis of lung cancer treatment in Japan

2018/09　Preliminary analysis of the cost-effectiveness of pertuzmab In patients With HER2-positive breast cancer in Japan

2018/03　レセプトデータベースを用いた肝臓癌治療の医療費分析 

2017/02　A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women